Rayzebio, Inc.
Clinical trials sponsored by Rayzebio, Inc., explained in plain language.
-
Radioactive drug takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New dynamic duo targets Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests two new drugs: one to help spot liver cancer cells (RYZ811) and another to deliver treatment directly to them (RYZ801). It is for people with a type of liver cancer called GPC3-positive hepatocellular carcinoma that cannot be removed by surgery. The goal is to se…
Phase: PHASE1, PHASE2 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New radioactive drug aims to fight gut tumors that resist standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC